These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31658837)

  • 1. CLSI - EUCAST: Comparison of antibiotic-susceptibility profile of
    Palmeira JD; Ferreira H
    Acta Microbiol Immunol Hung; 2019 Dec; 66(4):413-422. PubMed ID: 31658837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
    Hombach M; Mouttet B; Bloemberg GV
    J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
    Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
    J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
    Liu PY; Shi ZY; Tung KC; Shyu CL; Chan KW; Liu JW; Wu ZY; Kao CC; Huang YC; Lin CF
    J Infect Dev Ctries; 2014 Mar; 8(3):289-96. PubMed ID: 24619258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.
    Hombach M; Bloemberg GV; Böttger EC
    J Antimicrob Chemother; 2012 Mar; 67(3):622-32. PubMed ID: 22167240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
    Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
    Cantón R; Canut A; Morosini MI; Oliver A
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Flamm RK; Castanheira M
    J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST].
    Süzük S; Kaşkatepe B; Avcıküçük H; Aksaray S; Başustaoğlu A
    Mikrobiyol Bul; 2015 Oct; 49(4):494-501. PubMed ID: 26649407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms.
    Wolfensberger A; Sax H; Weber R; Zbinden R; Kuster SP; Hombach M
    PLoS One; 2013; 8(11):e79130. PubMed ID: 24223893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum β-lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia.
    Zeynudin A; Pritsch M; Schubert S; Messerer M; Liegl G; Hoelscher M; Belachew T; Wieser A
    BMC Infect Dis; 2018 Oct; 18(1):524. PubMed ID: 30342476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.
    Chen YH; Hsueh PR; Badal RE; Hawser SP; Hoban DJ; Bouchillon SK; Ni Y; Paterson DL
    J Infect; 2011 Apr; 62(4):280-91. PubMed ID: 21382411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from CLSI to EUCAST XL susceptibility breakpoint: its implication in urinary tract infection in men.
    Aguirre-Quiñonero A; Lecaroz Agara MC; Canut Blasco A
    Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1813-1815. PubMed ID: 29936620
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of antimicrobial susceptibility interpretation among Enterobacteriaceae using CLSI and EUCAST breakpoints.
    Suravaram S; Hada V; Ahmed Siddiqui I
    Indian J Med Microbiol; 2021 Jul; 39(3):315-319. PubMed ID: 34016471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam.
    Cheng NC; Liu CY; Huang YT; Liao CH; Teng LJ; Hsueh PR
    J Antimicrob Chemother; 2012 Jun; 67(6):1413-21. PubMed ID: 22345386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
    Kassim A; Omuse G; Premji Z; Revathi G
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.